Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial

Table 4 Significant associations between hemagglutination Inhibition (HAI) titers and demographic measures (age, gender, race, ethnicity), site, treatment group, year of study, and statin use assessed using a linear regression model^a

Influenza Vaccine Strain	Measure	Median Titer	GMT^b	p-value
H1N1	Sex			0.0245
	Male	80	100.9
	Female	160	127.3
	Ethnicity			0.0196
	Hispanic	96.6	109.1
	Non-Hispanic	80	85.4
	Other	160	156.4
H3N2	Treatment Group			0.0145
	allV3	160	257.8
	HD-IIV3	160	326.5
	Site			0.0010
	Boston Medical Center	160	226.1
	Cincinnati Children’s Hospital	160	446.4
	Duke University	160	241.9
	Year of Study			< 0.0001
	2017–2018	320	452.2
	2018–2019	160	186.1
Influenza B	Gender			0.0025
	Male	40	28.9
	Female	20	20.8
	Age Group			0.0001
	65–79	20	18.7
	80 +	40	32.2
	Year of Study			< 0.0001
	2017–2018	40	32.6
	2018–2019	20	18.5

^aAny of the independent variables (age, gender, race, ethnicity), site, treatment group, year of study, and statin use not presented per influenza strain were not significant in these regression analyses
^bThe GMTs for each outcome measure are adjusted in the model based on the other covariates

ISSN: 1742-4933